On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...

They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months.

Enzeevu (aflibercept-abzv), a biosimilar developed by Sandoz, demonstrated biosimilarity to reference aflibercept (Eylea) in ...

2 January 2024 District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's ...